CALGARY, July 28, 2017 /CNW/ - Middlefield Healthcare & Life Sciences Dividend Fund announced that it has filed a notice with the Toronto Stock Exchange (the "TSX") and received its approval to make a normal course issuer bid ("NCIB"). Purchases pursuant to the NCIB will be made in the open market through the facilities of the TSX. This NCIB will commence on August 4, 2017 and will terminate on August 3, 2018. In accordance with the Declaration of Trust by which the Fund is governed, market purchases pursuant to its NCIB may be effected by the Fund.
The Fund had 10,200,000 units issued and outstanding as at July 25, 2017. The Fund may, during the 12 month period commencing August 4, 2017 purchase on the TSX up to 1,016,000 units, being 10% of the public float and may not, in any 30 day period, purchase more than 204,000 units, being 2% of the units issued and outstanding. The Fund will cancel all units purchased pursuant to the bid. Subject to receiving all necessary regulatory approvals, the Fund may, in lieu of canceling units acquired, hold the units in treasury for resale. Middlefield Healthcare & Life Sciences Dividend Fund is implementing the NCIB to allow it to purchase units if and when it makes sense to do so.
Middlefield Healthcare & Life Sciences Dividend Fund trades on the Toronto Stock Exchange under the symbol "LS.UN".
This press release may contain forward-looking information, including with respect to future purchases of Units by the Corporation. The forward-looking information contained in this press release constitutes current expectations, as of the date of this press release, with respect to the matters covered hereby. Investors and others should not assume that any forward-looking statement contained in this press release represents an estimate as of any date other than the date of this press release.
SOURCE Middlefield Healthcare & Life Sciences Dividend Fund
For further information: visit our website at www.middlefield.com or contact the undersigned: Nancy Tham, Managing Director, Sales and Marketing, (888) 890-1868